Skip to main content
. Author manuscript; available in PMC: 2014 Aug 20.
Published in final edited form as: JAMA. 2013 Dec 25;310(24):2658–2667. doi: 10.1001/jama.2013.283815

Figure 1. Screening, Randomization and Follow-up.

Figure 1

63 patients (26 placebo, 37 diflunisal) remained on drug for 24 months. Analyzable primary outcome data were obtained on 60 of these patients (23 placebo, 37 diflunisal); 3 placebo patients had inadmissible NIS+7 data. Study drug was discontinued prior to 24 months in 67 patients (40 placebo, 27 diflunisal); 24 month primary outcome data (NIS+7) were obtained on 8 of these patients (5 placebo, 3 diflunisal).